The cost to Astrazeneca of building Brilinta
Thales, the final Brilinta outcome trial in Astrazeneca’s huge Parthenon programme, has hit – but the UK group’s vast investment in its blood thinner has yet to pay off.
Enhertu succeeds where Kadcyla and others failed
In gastric cancer the Astra/Daiichi drug could tie a second string to its bow, but toxicities might put a dampener on forecasts.
Novo Nordisk’s quiet entry into the year of Alzheimer’s
An upcoming study could show whether diabetes drugs like Novo’s Victoza might have an effect on slowing cognitive decline.
The joker in Exelixis and Bristol’s kidney cancer pack
The first-line Checkmate-9ER study will read out soon, and could show whether two arch rivals can together defeat a common enemy.
Amarin enters the home stretch
After an overwhelmingly positive adcom, the outstanding question around Vascepa is just how big the product might become.
Bristol might play a role in front-line lung cancer after all
The Checkmate-9LA trial of Opdivo plus Yervoy yesterday read out positively for overall survival.
Esmo 2019 – A place for Parps in prostate cancer
Lynparza looks set to add a third tumour type to its label, strengthening the grip of Astrazeneca and Merck & Co on the Parp inhibitor market.
Esmo 2019 – Glaxo’s Parp ambitions get a boost
The Prima trial delivers a convincing win for Glaxosmithkline’s Parp inhibitor Zejula, which looks to have a good chance of winning a broader label in ovarian cancer.
Esmo 2019 – Lynparza pushes Parps forward again
The Paola-1 study of Astrazeneca and Merck & Co’s Lynparza plus Avastin shows that more ovarian cancer patients can benefit from Parp inhibition, though the role of…
